DK2598659T3 - Fremgangsmåde til anvendelse af genekspression til bestemmelse af prognose for prostatacancer - Google Patents

Fremgangsmåde til anvendelse af genekspression til bestemmelse af prognose for prostatacancer Download PDF

Info

Publication number
DK2598659T3
DK2598659T3 DK11813024.4T DK11813024T DK2598659T3 DK 2598659 T3 DK2598659 T3 DK 2598659T3 DK 11813024 T DK11813024 T DK 11813024T DK 2598659 T3 DK2598659 T3 DK 2598659T3
Authority
DK
Denmark
Prior art keywords
expression
genes
gene
tumor
recurrence
Prior art date
Application number
DK11813024.4T
Other languages
English (en)
Inventor
Steven Shak
Frederick L Baehner
Tara Maddala
Mark Lee
Robert J Pelham
Wayne Cowens
Diana Cherbavaz
Michael C Kiefer
Michael Crager
Audrey Goddard
Joffre B Baker
Original Assignee
Genomic Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genomic Health Inc filed Critical Genomic Health Inc
Application granted granted Critical
Publication of DK2598659T3 publication Critical patent/DK2598659T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Claims (14)

1. Fremgangsmåde til bestemmelse af sandsynligheden for cancerrecidiv hos en patient med prostatacancer, der omfatter: måling af ekspressionsniveauet af GSTM2 i en biologisk prøve, der omfatter prostatavæv opnået fra patienten; forudsigelse af sandsynligheden for cancerrecidiv for patienten; hvor et forhøjet ekspressionsniveau af GSTM2 er negativt forbundet med en forøget risiko for recidiv.
2. Fremgangsmåde ifølge krav 1, hvor ekspressionsniveauet måles ved anvendelse af et RNA-transkript af GSTM2.
3. Fremgangsmåde ifølge krav 1, der yderligere omfatter normalisering af ekspressionsniveauet til opnåelse af et normaliseret ekspressionsniveau.
4. Fremgangsmåde ifølge krav 1, 2 eller 3, hvor sandsynligheden for cancerrecidiv er baseret på klinisk recidivfrit interval (cRFI).
5. Fremgangsmåde ifølge krav 1, 2 eller 3, hvor sandsynligheden for cancerrecidiv er baseret på biokemisk recidivfrit interval (bRFI).
6. Fremgangsmåde ifølge et hvilket som helst af ovennævnte krav, hvor den biologiske prøve har en positiv TMPRSS2- fusionsstatus.
7. Fremgangsmåde ifølge et hvilket som helst af ovennævnte krav, hvor den biologiske prøve har en negativ TMPRSS2- fusionsstatus.
8. Fremgangsmåde ifølge et hvilket som helst af ovennævnte krav, hvor patienten har prostatacancer i tidligt stadium.
9. Fremgangsmåde ifølge et hvilket som helst af ovennævnte krav, hvor den biologiske prøve omfatter prostatatumorvæv med det primære Gleason-mønster for prostatatumoren.
10. Fremgangsmåde ifølge et hvilket som helst af ovennævnte krav, hvor den biologiske prøve omfatter prostatatumorvæv med det højeste Gleason-mønster for prostatatumoren.
11. Fremgangsmåde ifølge et hvilket som helst af ovennævnte krav, hvor den biologiske prøve er prostatatumorvæv.
12. Fremgangsmåde ifølge et hvilket som helst af ovennævnte krav, hvor den biologiske prøve er non-tumorprostatavæv.
13. Fremgangsmåde ifølge et hvilket som helst af ovennævnte krav, der yderligere omfatter bestemmelse af sandsynligheden for opgradering eller udvikling til et højere stadium for patienten med prostatacancer, hvor et forhøjet ekspressionsniveau af GSTM2 er negativt forbundet med en forøget risiko for opgradering/udvikling til et højere stadium.
14. Fremgangsmåde ifølge et hvilket som helst af ovennævnte krav, hvor den biologiske prøve er en fikseret, paraffinindstøbt vævsprøve.
DK11813024.4T 2010-07-27 2011-07-25 Fremgangsmåde til anvendelse af genekspression til bestemmelse af prognose for prostatacancer DK2598659T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US36821710P 2010-07-27 2010-07-27
US41431010P 2010-11-16 2010-11-16
US201161485536P 2011-05-12 2011-05-12
PCT/US2011/045253 WO2012015765A2 (en) 2010-07-27 2011-07-25 Method for using gene expression to determine prognosis of prostate cancer

Publications (1)

Publication Number Publication Date
DK2598659T3 true DK2598659T3 (da) 2015-05-26

Family

ID=45527113

Family Applications (3)

Application Number Title Priority Date Filing Date
DK11813024.4T DK2598659T3 (da) 2010-07-27 2011-07-25 Fremgangsmåde til anvendelse af genekspression til bestemmelse af prognose for prostatacancer
DK15152517.7T DK2913405T3 (da) 2010-07-27 2011-07-25 Fremgangsmåde til anvendelse af genekspression til bestemmelse af prognosen for prostatacancer
DK16195347.6T DK3147373T3 (da) 2010-07-27 2011-07-25 Fremgangsmåde til anvendelse af genekspression til at bestemme prognosen for prostatacancer

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK15152517.7T DK2913405T3 (da) 2010-07-27 2011-07-25 Fremgangsmåde til anvendelse af genekspression til bestemmelse af prognosen for prostatacancer
DK16195347.6T DK3147373T3 (da) 2010-07-27 2011-07-25 Fremgangsmåde til anvendelse af genekspression til at bestemme prognosen for prostatacancer

Country Status (12)

Country Link
US (6) US20120028264A1 (da)
EP (5) EP2913405B1 (da)
JP (5) JP2013532482A (da)
AU (1) AU2011282892B2 (da)
CA (2) CA3081061C (da)
DK (3) DK2598659T3 (da)
ES (4) ES2925983T3 (da)
IL (5) IL243205A (da)
MX (4) MX346031B (da)
NZ (1) NZ607282A (da)
SG (3) SG10201912361VA (da)
WO (1) WO2012015765A2 (da)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100233691A1 (en) * 2007-03-30 2010-09-16 Source Precision Medicine, Inc. D/B/A Source Mdx Gene Expression Profiling for Identification, Monitoring and Treatment of Prostate Cancer
US20120041274A1 (en) 2010-01-07 2012-02-16 Myriad Genetics, Incorporated Cancer biomarkers
CA2804391A1 (en) 2010-07-07 2012-01-12 Myriad Genetics, Inc. Gene signatures for cancer prognosis
DK2598659T3 (da) 2010-07-27 2015-05-26 Genomic Health Inc Fremgangsmåde til anvendelse af genekspression til bestemmelse af prognose for prostatacancer
WO2012030840A2 (en) 2010-08-30 2012-03-08 Myriad Genetics, Inc. Gene signatures for cancer diagnosis and prognosis
CA2863040C (en) 2012-01-31 2022-04-19 Genomic Health, Inc. Gene expression profile algorithm and test for determining prognosis of prostate cancer
TW201343920A (zh) * 2012-03-29 2013-11-01 財團法人國家衛生研究院 預測前列腺癌預後之分子標記、方法與套組
BR102012007246A2 (pt) * 2012-03-30 2016-02-10 Fundação Antonio Prudente métodos para prognóstico e classificação de resultados de um evento
WO2013155371A1 (en) * 2012-04-12 2013-10-17 Cornell University MiRNA-31 AS A DIAGNOSTIC, PROGNOSTIC AND THERAPEUTIC AGENT IN CANCER
GB201207722D0 (en) 2012-05-02 2012-06-13 Bergenbio As Method
US20150218646A1 (en) * 2012-07-20 2015-08-06 Diagnocure Inc Methods, kits and compositions for providing a clinical assessment of prostate cancer
CN102816862A (zh) * 2012-09-19 2012-12-12 南开大学 miRNA 222在前列腺癌血清学诊断试剂盒中的应用
WO2014071226A1 (en) * 2012-11-02 2014-05-08 The Regents Of The University Of California Methods and systems for determining a likelihood of adverse prostate cancer pathology
EP4190918A1 (en) 2012-11-16 2023-06-07 Myriad Genetics, Inc. Gene signatures for cancer prognosis
GB201322034D0 (en) 2013-12-12 2014-01-29 Almac Diagnostics Ltd Prostate cancer classification
AU2014373927B2 (en) * 2013-12-30 2018-03-22 Genomatix Prostate cancer gene profiles and methods of using the same
JP6666852B2 (ja) * 2014-01-16 2020-03-18 イルミナ インコーポレイテッド 前立腺がん再発の予後に関する遺伝子発現パネル
WO2015175692A1 (en) * 2014-05-13 2015-11-19 Myriad Genetics, Inc. Gene signatures for cancer prognosis
US10801072B2 (en) 2014-09-04 2020-10-13 Miodx Method of analysis allowing avoidance of surgery
EP3245302B8 (en) * 2015-01-14 2022-01-19 Ohio State Innovation Foundation Mirna-based predictive models for diagnosis and prognosis of prostate cancer
ES2749651T3 (es) 2015-02-11 2020-03-23 Region Midtjylland Método basado en microARN para la detección temprana de cáncer de próstata en muestras de orina
CA2977439C (en) 2015-02-27 2025-05-20 Aarhus Universitet MICRORNA-BASED METHOD FOR EVALUATING THE PROGNOSIS OF A PATIENT WITH PROSTATE CANCER
CN104880565A (zh) * 2015-05-04 2015-09-02 贵州省人民医院 Zfp36前列腺癌预后诊断的检测试剂及其试剂盒
DK3303618T3 (da) * 2015-05-29 2019-12-16 Koninklijke Philips Nv Fremgangsmåder til prognose af prostatacancer
US20170107580A1 (en) 2015-10-15 2017-04-20 Dendreon Pharmaceuticals, Inc. Gene expression markers for predicting overall survival in subjects treated with sipuleucel-t
US11971411B2 (en) * 2016-01-20 2024-04-30 Dana-Farber Cancer Institute, Inc. Compositions and methods for screening and identifying clinically aggressive prostate cancer
WO2017136603A1 (en) 2016-02-02 2017-08-10 Guardant Health, Inc. Cancer evolution detection and diagnostic
WO2017210662A1 (en) * 2016-06-03 2017-12-07 Castle Biosciences, Inc. Methods for predicting risk of recurrence and/or metastasis in soft tissue sarcoma
US10724089B2 (en) 2016-10-06 2020-07-28 The Board Of Trustees Of The University Of Illinois Spatial molecular analysis of tissue
WO2018098241A1 (en) * 2016-11-22 2018-05-31 University Of Rochester Methods of assessing risk of recurrent prostate cancer
GB201619808D0 (en) * 2016-11-23 2017-01-04 Univ London Queen Mary Biomarkers for the prognosis and diagnosis of cancer
EP3743533A1 (en) * 2018-01-25 2020-12-02 Sorbonne Universite Molecular signature and use thereof for the identification of indolent prostate cancer
WO2019165021A1 (en) * 2018-02-22 2019-08-29 Liquid Biopsy Research LLC Methods for prostate cancer detection and treatment
WO2020214718A1 (en) * 2019-04-16 2020-10-22 Memorial Sloan Kettering Cancer Center Rrm2 signature genes as prognostic markers in prostate cancer patients
JP2020195314A (ja) * 2019-05-31 2020-12-10 医薬資源研究所株式会社 疾患・体質の分析方法、疾患・体質の分析システム、プログラムおよびコンピュータ読み取り可能な記録媒体
CN114423874A (zh) * 2019-07-05 2022-04-29 英特莱克森有限责任公司 个体hla分型的确定方法及其作为预测因子、靶基因和治疗剂的用途
WO2021124455A1 (ja) * 2019-12-17 2021-06-24 株式会社 東芝 分析方法及びキット
WO2021122735A1 (en) * 2019-12-19 2021-06-24 F. Hoffmann-La Roche Ag Use of sept9 inhibitors for treating hepatitis b virus infection
US20230070840A1 (en) * 2020-01-30 2023-03-09 Arocell Ab Predicting patient survival
EP3885453A1 (en) * 2020-03-23 2021-09-29 Koninklijke Philips N.V. Prediction of radiotherapy response for prostate cancer subject based on dna repair genes
US11845993B2 (en) * 2020-03-24 2023-12-19 The Regents Of The University Of Michigan Methods for identifying prostate cancer
CA3186853A1 (en) * 2020-07-23 2022-01-27 John Mansell Compositions and methods for treating pain and anxiety disorders
ES1277194Y (es) 2021-03-25 2021-11-26 Keyzell Holding Sl Sistema basado en inteligencia artificial para analizar biomarcadores y personalizar tratamientos para cáncer
EP4660323A1 (en) 2023-01-30 2025-12-10 Jichi Medical University Prognosis prediction method for metastatic hormone-sensitive prostate cancer
CN116640734B (zh) * 2023-06-17 2025-01-24 青岛农业大学 关键基因在体外调控卵母细胞gvbd的用途及干扰片段

Family Cites Families (170)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997000449A1 (en) 1995-06-14 1997-01-03 Aberdeen University Prognostic and therapeutic system for cancer
US6300060B1 (en) 1995-11-09 2001-10-09 Dana-Farber Cancer Institute, Inc. Method for predicting the risk of prostate cancer morbidity and mortality
USRE38490E1 (en) 1995-11-16 2004-04-06 Baylor College Of Medicine Method for identifying metastatic sequences
US5712097A (en) 1996-01-19 1998-01-27 The Johns Hopkins University School Of Medicine Tumor suppressor gene, DPC4
CA2261019A1 (en) 1996-07-15 1998-01-22 Mayo Foundation For Medical Education And Research Methods to detect hk2 polypeptides
US6479263B1 (en) 1996-11-14 2002-11-12 Baylor College Of Medicine Method for detection of micrometastatic prostate cancer
US6190857B1 (en) 1997-03-24 2001-02-20 Urocor, Inc. Diagnosis of disease state using MRNA profiles in peripheral leukocytes
WO1999004238A2 (en) 1997-07-15 1999-01-28 Mitotix, Inc. Reagents and methods for diagnosis and prognosis of proliferative disorders
US20020165143A1 (en) 1997-12-03 2002-11-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
FI980488A7 (fi) 1998-03-04 1999-09-05 Arctic Partners Oy Ab Uusi diagnostinen menetelmä
WO1999064627A2 (en) 1998-06-06 1999-12-16 Genostic Pharma Limited Probes used for genetic profiling
GB2339200B (en) 1998-06-06 2001-09-12 Genostic Pharma Ltd Genostics
US6902892B1 (en) 1998-10-19 2005-06-07 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
WO2000040749A2 (en) 1999-01-06 2000-07-13 Genenews Inc. Method for the detection of gene transcripts in blood and uses thereof
JP4495349B2 (ja) 1999-01-28 2010-07-07 ジェン−プローブ・インコーポレーテッド 癌の遺伝マーカーを生物学的サンプルにおいて検出するための核酸配列
US20030207808A1 (en) 1999-02-18 2003-11-06 Kinneret Savitzky Novel nucleic acid and amino acid sequences
FI990382A0 (fi) 1999-02-23 1999-02-23 Arctic Partners Oy Ab Uusi diagnostinen menetelmä
WO2000061744A1 (fr) 1999-04-09 2000-10-19 Chugai Research Institute For Molecular Medicine, Inc. Nouveaux genes de foetus
US6692916B2 (en) 1999-06-28 2004-02-17 Source Precision Medicine, Inc. Systems and methods for characterizing a biological condition or agent using precision gene expression profiles
US6960439B2 (en) 1999-06-28 2005-11-01 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
GB9926805D0 (en) 1999-11-13 2000-01-12 Zeneca Ltd Diagnostic methods
DE60137829D1 (de) * 2000-01-13 2009-04-16 Genentech Inc Menschliche stra6 polypeptide
US6448086B1 (en) 2000-01-18 2002-09-10 Diagnostic Systems Laboratories, Inc. Insulin-like growth factor system and cancer
US6566130B1 (en) 2000-01-28 2003-05-20 Henry M. Jackson Foundation For The Advancement Of Military Medicine Androgen-regulated gene expressed in prostate tissue
US7700359B2 (en) 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
WO2002031209A2 (en) 2000-10-13 2002-04-18 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Genes related to development of refractory prostate cancer
AU2002216009A1 (en) 2000-11-03 2002-05-15 Michael Giesing Clinical and functional validation of targets from disseminated cancer cells
US20030087818A1 (en) 2001-02-02 2003-05-08 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
WO2002079411A2 (en) 2001-03-29 2002-10-10 Van Andel Institute Microarray gene expression profiling in clear cell renal cell carcinoma: prognosis and drug target identification
JP2004530884A (ja) 2001-05-25 2004-10-07 マウント・シナイ・ホスピタル Ｅｐｈｂ２のキナーゼドメインを調節する方法
US20030138793A1 (en) 2001-06-10 2003-07-24 Irm Llc, A Delaware Limited Liability Company Molecular signatures of commonly fatal carcinomas
US20030108963A1 (en) 2001-07-25 2003-06-12 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kit, and methods for identification, assessment, prevention and therapy of prostate cancer
US20100297657A1 (en) 2001-08-02 2010-11-25 The Regents Of The University Of Michigan Expression profile of prostate cancer
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
US7700293B2 (en) 2001-08-02 2010-04-20 The Regents Of The University Of Michigan Expression profile of prostate cancer
CN102402650A (zh) 2001-11-09 2012-04-04 生命技术公司 利用基因表达分布图识别、监控和治疗疾病以及鉴定生物学状态
WO2003050243A2 (en) 2001-12-10 2003-06-19 Millennium Pharmaceuticals Inc. Novel genes encoding colon cancer antigens
US6949342B2 (en) 2001-12-21 2005-09-27 Whitehead Institute For Biomedical Research Prostate cancer diagnosis and outcome prediction by expression analysis
US20030215835A1 (en) 2002-01-15 2003-11-20 Zairen Sun Differentially-regulated prostate cancer genes
EP1483381A2 (fr) 2002-03-14 2004-12-08 Exonhit Therapeutics S.A. Variants de kallikrein-2 et kallikreine-3 humaines et leurs utilisations
AUPS187002A0 (en) * 2002-04-22 2002-05-30 Queensland University Of Technology Condition-specific molecules and uses therefor
CA2498418A1 (en) 2002-09-10 2004-03-25 Guennadi V. Glinskii Gene segregation and biological sample classification methods
US20060051763A1 (en) 2002-09-25 2006-03-09 Anu-Maria Loukola Detection methods
WO2004053106A2 (en) 2002-12-05 2004-06-24 Regulome Corporation Profiled regulatory sites useful for gene control
AU2004209578A1 (en) 2003-02-07 2004-08-19 Diagnocure Inc. Method to detect prostate cancer in a sample
WO2004077942A2 (en) 2003-02-28 2004-09-16 Genpath Pharmaceuticals, Incorporated Inducible prostate cancer model
EP1620573A4 (en) 2003-04-15 2006-12-20 Avalon Pharmaceuticals DETERMINATION OF CANCER-ASSOCIATED GENES AND THERAPEUTIC OBJECTS USING MOLECULAR CYTOGENETIC PROCEDURES
WO2004108896A2 (en) * 2003-06-03 2004-12-16 The Board Of Trustees Of The University Of Arkansas Gene expression profiling of uterine serous papillary carcinomas and ovarian serous papillary tumors
EP3170906B1 (en) 2003-06-24 2018-08-22 Genomic Health, Inc. Prediction of likelihood of cancer recurrence
EP3330875B1 (en) * 2003-07-10 2021-12-01 Genomic Health, Inc. Expression profile algorithm and test for prognosing breast cancer recurrence
US20070048738A1 (en) 2003-07-14 2007-03-01 Mayo Foundation For Medical Education And Research Methods and compositions for diagnosis, staging and prognosis of prostate cancer
AU2004262369A1 (en) 2003-07-29 2005-02-10 Bristol-Myers Squibb Company Biomarkers of cyclin-dependent kinase modulation
AU2004298604B2 (en) 2003-12-15 2010-09-23 The Regents Of The University Of California Molecular signature of the PTEN tumor suppressor
JP2008504803A (ja) 2004-01-09 2008-02-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 遺伝子発現の細胞型特異的パターン
GB0400976D0 (en) 2004-01-16 2004-02-18 Univ Cambridge Tech Methods of diagnosis
WO2005076005A2 (en) 2004-01-30 2005-08-18 Medizinische Universität Wien A method for classifying a tumor cell sample based upon differential expression of at least two genes
JP2005211023A (ja) 2004-01-30 2005-08-11 Hayashibara Biochem Lab Inc 腎細胞癌の転移若しくは再発の可能性を予測する方法
WO2005083128A2 (en) 2004-02-25 2005-09-09 University Of South Florida Methods for predicting cancer outcome and gene signatures for use therein
US20070224596A1 (en) 2004-04-09 2007-09-27 Mariana Nacht Compositions and methods for the modifying hypoxia induced gene regulation
US7871769B2 (en) 2004-04-09 2011-01-18 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
EP1740951B1 (en) 2004-04-29 2008-03-05 Marc Ramael Method and kit for detecting components in a sample
CA2565450C (en) 2004-05-07 2018-03-06 Gyorgy Petrovics Methods of diagnosing or treating prostate cancer using the erg gene, alone or in combination with other over or under expressed genes in prostate cancer
AU2005249446A1 (en) 2004-05-27 2005-12-15 Vertex Pharmaceuticals Incorporated Biomarkers for monitoring inhibition of IMPDH pathway
EP1756309A2 (en) 2004-06-03 2007-02-28 Bayer HealthCare AG Methods for predicting and monitoring response to cancer therapy
WO2006005043A2 (en) 2004-06-30 2006-01-12 Cemines, Inc. Compositions and methods for detecting protein interactions with target dna sequences
US7587279B2 (en) 2004-07-06 2009-09-08 Genomic Health Method for quantitative PCR data analysis system (QDAS)
CN102680686A (zh) 2004-08-13 2012-09-19 千年药品公司 用于鉴定、评估、预防和治疗前列腺癌的基因、组合物、试剂盒和方法
US7572640B2 (en) 2004-09-28 2009-08-11 Singulex, Inc. Method for highly sensitive detection of single protein molecules labeled with fluorescent moieties
CA2585571C (en) * 2004-11-05 2020-01-21 Genomic Health, Inc. Predicting response to chemotherapy using gene expression markers
EP1824995A2 (en) 2004-11-24 2007-08-29 St. George's Enterprises Limited Diagnosis of prostate cancer
WO2006066240A2 (en) 2004-12-17 2006-06-22 Veridex Llc Methods for assessing patients with acute myeloid leukemia
US7943306B2 (en) 2005-01-12 2011-05-17 The Board Of Trustees Of The Leland Stanford Junior University Gene expression signature for prediction of human cancer progression
US8168602B2 (en) 2005-02-17 2012-05-01 Dana-Farber Cancer Institute, Inc. Compositions, kits and methods for identification, assessment, prevention and therapy of cancer
US7666595B2 (en) * 2005-02-25 2010-02-23 The Brigham And Women's Hospital, Inc. Biomarkers for predicting prostate cancer progression
EP1874471A4 (en) * 2005-03-16 2008-12-10 Sidney Kimmel Cancer Ct METHOD AND COMPOSITIONS FOR PREDICTING DEATH BY CANCER AND SURVIVAL OF PROSTATE CANCER USING GENE EXPRESSION SIGNATURES
WO2006105642A1 (en) 2005-04-05 2006-10-12 British Columbia Cancer Agency Biomarkers for the detection of lung cancer and uses thereof
US20090203639A1 (en) 2005-04-15 2009-08-13 Oncomethylome Sciences, Inc. Methylation Markers for Diagnoses and Treatment of Cancers
WO2006124836A1 (en) 2005-05-13 2006-11-23 Duke University Gene expression signatures for oncogenic pathway deregulation
US20080275652A1 (en) 2005-05-13 2008-11-06 Universite Libre De Bruxelles Gene-based algorithmic cancer prognosis
WO2006135596A2 (en) 2005-06-06 2006-12-21 The Regents Of The University Of Michigan Prognostic meta signatures and uses thereof
AU2006254834B2 (en) 2005-06-08 2012-09-20 Millennium Pharmaceuticals, Inc. Treatment of patients with cancer therapy
US20070099209A1 (en) 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20070105133A1 (en) 2005-06-13 2007-05-10 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
JP5512125B2 (ja) * 2005-09-12 2014-06-04 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 前立腺癌における再発性遺伝子融合
EP1951911A2 (en) 2005-11-08 2008-08-06 Euclid Diagnostics LLC Materials and methods for assaying for methylation of cpg islands associated with genes in the evaluation of cancer
EP1960551A2 (en) 2005-12-01 2008-08-27 Medical Prognosis Institute Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
US8445198B2 (en) 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
EP2546359A1 (en) 2005-12-08 2013-01-16 Novartis AG Effects of inhibitors of FGFR3 on gene transcription
US20090215054A1 (en) 2005-12-13 2009-08-27 Carter Scott L Prognosis indicators for solid human tumors
WO2007075672A2 (en) 2005-12-23 2007-07-05 Lankenau Institute For Medical Research Prognostic cancer markers
CA2636984A1 (en) 2006-01-11 2007-07-19 Genomic Health, Inc. Gene expression markers for colorectal cancer prognosis
ES2300176B1 (es) * 2006-02-15 2009-05-01 Consejo Superior Investig. Cientificas Metodo para el diagnostico molecular de cancer de prostata, kit para implementar el metodo.
US20070218512A1 (en) 2006-02-28 2007-09-20 Alex Strongin Methods related to mmp26 status as a diagnostic and prognostic tool in cancer management
US7888019B2 (en) 2006-03-31 2011-02-15 Genomic Health, Inc. Genes involved estrogen metabolism
US7914988B1 (en) 2006-03-31 2011-03-29 Illumina, Inc. Gene expression profiles to predict relapse of prostate cancer
US20090098538A1 (en) 2006-03-31 2009-04-16 Glinsky Gennadi V Prognostic and diagnostic method for disease therapy
WO2007140352A2 (en) 2006-05-26 2007-12-06 Invitrogen Corporation Plasma membrane and secreted cancer biomarkers
EP2029020A4 (en) 2006-06-22 2010-04-21 Wisconsin Alumni Res Found USE OF STROMA COLLAGEN IN THE DIAGNOSIS AND CHARACTERIZATION OF BREAST CANCER
US20100330602A1 (en) 2006-09-19 2010-12-30 Emory University Use of Soluble Galectin-3 (Gal-3) for Cancer Treatment
WO2008048570A2 (en) 2006-10-16 2008-04-24 The Ohio State University Research Foundation Piwil2-related biomarkers and cell lines useful therewith
WO2008046510A1 (en) 2006-10-16 2008-04-24 Bayer Healthcare Ag Fn1 as a biomarker, therapeutic and diagnostic target
WO2008067065A2 (en) * 2006-10-19 2008-06-05 Shiv Srivastava Methods, kits, and systems for diagnosing and prognosing prostate cancer using secreted biomarkers
US8338109B2 (en) 2006-11-02 2012-12-25 Mayo Foundation For Medical Education And Research Predicting cancer outcome
US20080254481A1 (en) 2006-11-13 2008-10-16 Invitrogen Corporation Methods and kits for detecting prostate cancer biomarkers
US20080131887A1 (en) 2006-11-30 2008-06-05 Stephan Dietrich A Genetic Analysis Systems and Methods
US20100015620A1 (en) 2006-12-06 2010-01-21 Strovel Jeffrey W Cancer-linked genes as biomarkers to monitor response to impdh inhibitors
AT504702A1 (de) 2006-12-22 2008-07-15 Arc Austrian Res Centers Gmbh Set von tumormarkern
US20100120788A1 (en) 2007-01-09 2010-05-13 Bristol-Myers Squibb Company Identification of polynucleotides for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine kinase pathways in prostate cells
US20090047694A1 (en) 2007-08-17 2009-02-19 Shuber Anthony P Clinical Intervention Directed Diagnostic Methods
CA2680591A1 (en) 2007-03-15 2008-09-25 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
WO2008122447A2 (en) 2007-04-10 2008-10-16 Epigenomics Ag Dna methylation assay for the diagnosis or prognosis of medical conditions
US20110091377A1 (en) 2007-05-11 2011-04-21 The Johns Hopkins University Biomarkers for melanoma
US20110030074A1 (en) 2007-05-21 2011-02-03 Dana Farber Cancer Institute, Inc. Compositions and methods for cancer gene discovery
WO2009021338A1 (en) 2007-08-15 2009-02-19 UNIVERSITé DE SHERBROOKE Alternative splicing gene variants in cancer detection
US20110306507A1 (en) 2007-09-07 2011-12-15 Universite Libre De Bruxelles Method and tools for prognosis of cancer in her2+partients
WO2009051734A1 (en) 2007-10-17 2009-04-23 The General Hospital Corporation Microchip-based devices for capturing circulating tumor cells and methods of their use
GB0721605D0 (en) 2007-11-02 2007-12-12 Cancer Rec Tech Ltd Prostrate cancer susceptibility screening
US20090123439A1 (en) 2007-11-09 2009-05-14 The Jackson Laboratory Diagnostic and prognosis methods for cancer stem cells
WO2009070767A2 (en) 2007-11-28 2009-06-04 Whitehead Institute For Biomedical Research Systemic instigation systems to study tumor growth or metastasis
EP2065474A1 (en) 2007-11-28 2009-06-03 Siemens Healthcare Diagnostics GmbH A method to assess prognosis and to predict therapeutic response to endocrine treatment
WO2009068423A2 (en) 2007-11-30 2009-06-04 Siemens Healthcare Diagnostics Gmbh Method for predicting therapy responsiveness in basal like tumors
WO2009089521A2 (en) 2008-01-10 2009-07-16 Nuvera Biosciences, Inc. Predictors for evaluating response to cancer therapy
WO2009105154A2 (en) 2008-02-19 2009-08-27 The Jackson Laboratory Diagnostic and prognostic methods for cancer
WO2009105640A1 (en) 2008-02-22 2009-08-27 Virginia Commonwealth University Signatures associated with rejection or recurrence of cancer
US8067178B2 (en) 2008-03-14 2011-11-29 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
SG177938A1 (en) 2008-03-26 2012-02-28 Theranos Inc Methods and systems for assessing clinical outcomes
EP2105511A1 (en) 2008-03-28 2009-09-30 Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. Medicament compositions and substances for treatment and identifying adenocarcinoma of the lung
US20110053804A1 (en) 2008-04-03 2011-03-03 Sloan-Kettering Institute For Cancer Research Gene Signatures for the Prognosis of Cancer
EP2288722B1 (en) 2008-04-10 2014-11-05 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Prostate cancer-specific alterations in erg gene expression and detection and treatment methods based on those alterations
US20110124003A1 (en) 2008-04-25 2011-05-26 Integrated Bioscience Solutions, Llc Cytological Methods for Detecting Cancer
US8093000B2 (en) 2008-05-09 2012-01-10 The Regents Of The University Of California Methods for predicting and treating tumors resistant to drug, immunotherapy, and radiation
CA2724433A1 (en) 2008-05-14 2009-11-19 Eth Zuerich Method for biomarker and drug-target discovery for prostate cancer diagnosis and treatment as well as biomarker assays determined therewith
JP2011523551A (ja) 2008-05-15 2011-08-18 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 血管形成の調節の新規ターゲット
WO2009140741A1 (en) 2008-05-23 2009-11-26 The University Of Queensland Agents and methods for diagnosing the presence or risk of prostate cancer
GB0809689D0 (en) 2008-05-28 2008-07-02 Cancer Res Inst Royal Markers for prostate cancee
CA2725978A1 (en) 2008-05-28 2009-12-03 Genomedx Biosciences, Inc. Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
US20090298082A1 (en) * 2008-05-30 2009-12-03 Klee George G Biomarker panels for predicting prostate cancer outcomes
WO2009149166A2 (en) 2008-06-03 2009-12-10 Children's Hospital Medical Center Methods and compositions for the diagnosis and treatment of proliferative disorders
WO2010003773A1 (en) 2008-06-16 2010-01-14 Siemens Medical Solutions Diagnostics Gmbh Algorithms for outcome prediction in patients with node-positive chemotherapy-treated breast cancer
EP2405022A3 (en) 2008-07-08 2012-05-02 Genomic Health, Inc. Gene expression profiling for predicting the survivability of prostate cancer subjects
KR20110052627A (ko) 2008-07-16 2011-05-18 다나-파버 캔서 인스티튜트 인크. 전립선암과 관련된 시그너처 및 ｐｃ결정인자 및 그의 사용 방법
AU2009274563A1 (en) 2008-07-21 2010-01-28 Texas A & M University Methods for diagnosis and prognosis of skin cancer
US9103819B2 (en) 2008-09-10 2015-08-11 Rheinische Friedrich-Wilhelms-Universität Bonn Peripheral zone tumor cells, methods for their preparation and use
AU2009306260B2 (en) 2008-10-20 2015-12-24 Valipharma Methods and uses involving genetic aberrations of NAV3 and aberrant expression of multiple genes
AU2009307651A1 (en) 2008-10-22 2010-04-29 Genentech, Inc. Prostate stem cells and uses thereof
CN102308004A (zh) 2008-10-30 2012-01-04 卡里斯生命科学卢森堡控股有限责任公司 评价rna图案的方法
US20110230361A1 (en) * 2008-11-14 2011-09-22 Emory University Prostate cancer biomarkers to predict recurrence and metastatic potential
WO2010056351A2 (en) 2008-11-14 2010-05-20 Stc.Unm Gene expression classifiers for relapse free survival and minimal residual disease improve risk classification and out come prediction in pedeatric b-precursor acute lymphoblastic leukemia
GB0821787D0 (en) 2008-12-01 2009-01-07 Univ Ulster A genomic-based method of stratifying breast cancer patients
WO2010065940A1 (en) 2008-12-04 2010-06-10 The Regents Of The University Of California Materials and methods for determining diagnosis and prognosis of prostate cancer
US20120301887A1 (en) 2009-01-06 2012-11-29 Bankaitis-Davis Danute M Gene Expression Profiling for the Identification, Monitoring, and Treatment of Prostate Cancer
ES2991436T3 (es) 2009-01-07 2024-12-03 Myriad Genetics Inc Biomarcadores de cáncer
WO2010083252A2 (en) 2009-01-14 2010-07-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Ratio based biomarkers and methods of use thereof
JP2012515353A (ja) 2009-01-15 2012-07-05 ラボラトリー コーポレイション オブ アメリカ ホールディングス Ｈｅｒ−２発現の測定による患者の反応を判定する方法
EP2233590A1 (en) 2009-01-28 2010-09-29 AIT Austrian Institute of Technology GmbH Methylation assay
EP2399130A4 (en) 2009-02-20 2012-06-06 Wayne John Cancer Inst ASSAY OF B7-H3 ANTIBODY-COUPLED BEADS FOR THE ISOLATION AND DETECTION OF CIRCULATING TUMOR CELLS IN THE BODILY FLUIDS OF MELANOMA AND BREAST CANCER PATIENTS
WO2010099577A1 (en) 2009-03-04 2010-09-10 The University Of Queensland Cancer biomarkers and uses therefor
US8700789B2 (en) 2009-03-16 2014-04-15 Apple Inc. Accessory and mobile computing device communication using an application communication protocol
US8765383B2 (en) 2009-04-07 2014-07-01 Genomic Health, Inc. Methods of predicting cancer risk using gene expression in premalignant tissue
EP2241634A1 (en) 2009-04-16 2010-10-20 Université Libre de Bruxelles Diagnostic method and tools to predict the effiacy of targeted agents against IGF-1 pathway activation in cancer
CN105132544A (zh) 2009-04-16 2015-12-09 加拿大国家研究委员会 用于肿瘤特征和标记物组鉴定，肿瘤分级的方法和用于癌的标记物组
WO2010127399A1 (en) 2009-05-06 2010-11-11 Walter And Eliza Hall Institute Of Medical Research Gene expression profiles and uses thereof
WO2010129965A1 (en) 2009-05-08 2010-11-11 The Regents Of The University Of California Cancer specific mitotic network
US20100303795A1 (en) * 2009-05-27 2010-12-02 Soerensen Karina Dalsgaard Marker of prostate cancer
US10095829B2 (en) 2009-07-08 2018-10-09 Worldwide Innovative Network Computer implemented methods of treating lung cancer
WO2011039734A2 (en) 2009-10-02 2011-04-07 Enzo Medico Use of genes involved in anchorage independence for the optimization of diagnosis and treatment of human cancer
MX337650B (es) 2009-11-23 2016-03-14 Genomic Health Inc Metodos para predecir el desenlace clinico del cancer.
ES3027507T3 (en) 2010-01-11 2025-06-16 Genomic Health Inc Method to use gene expression to determine likelihood of clinical outcome of renal cancer
DK2598659T3 (da) 2010-07-27 2015-05-26 Genomic Health Inc Fremgangsmåde til anvendelse af genekspression til bestemmelse af prognose for prostatacancer
WO2014108896A1 (en) 2013-01-08 2014-07-17 Marpe Technologies Ltd. Device and method for body moles mapping and tracking

Also Published As

Publication number Publication date
EP2598659A2 (en) 2013-06-05
WO2012015765A3 (en) 2012-06-14
MX338883B (es) 2016-05-04
JP2016178921A (ja) 2016-10-13
EP2913405B1 (en) 2016-11-09
JP7042784B2 (ja) 2022-03-28
JP2022031750A (ja) 2022-02-22
CA3081061C (en) 2023-01-03
JP2018068299A (ja) 2018-05-10
HK1185116A1 (en) 2014-02-07
EP4083233A2 (en) 2022-11-02
ES2925983T3 (es) 2022-10-20
HK1212395A1 (en) 2016-06-10
US20200255911A1 (en) 2020-08-13
IL243206A (en) 2017-04-30
JP2020031642A (ja) 2020-03-05
ES2537403T3 (es) 2015-06-08
US20190249260A1 (en) 2019-08-15
US20220396842A1 (en) 2022-12-15
AU2011282892B2 (en) 2015-07-16
MX346031B (es) 2017-03-01
SG10201912361VA (en) 2020-02-27
WO2012015765A2 (en) 2012-02-02
MX359416B (es) 2018-09-27
SG186940A1 (en) 2013-02-28
CA2804626C (en) 2020-07-28
IL243205A (en) 2017-04-30
EP2598659B1 (en) 2015-03-11
DK3147373T3 (da) 2019-08-12
DK2913405T3 (da) 2017-02-13
CA2804626A1 (en) 2012-02-02
JP6246845B2 (ja) 2017-12-13
EP2598659A4 (en) 2014-01-01
ES2611000T3 (es) 2017-05-04
US10260104B2 (en) 2019-04-16
SG10201505769PA (en) 2015-09-29
EP3147373B1 (en) 2019-05-15
AU2011282892A1 (en) 2013-03-07
US20160097105A1 (en) 2016-04-07
EP3147373A1 (en) 2017-03-29
IL251403B (en) 2018-04-30
EP2913405A1 (en) 2015-09-02
MX2018011725A (es) 2021-11-16
MX2013000996A (es) 2013-12-09
CA3081061A1 (en) 2012-02-02
ES2741745T3 (es) 2020-02-12
EP3556870B1 (en) 2022-06-22
IL243203A (en) 2017-04-30
JP2013532482A (ja) 2013-08-19
IL243201A (en) 2017-04-30
US20250129432A1 (en) 2025-04-24
IL251403A0 (en) 2017-05-29
EP3556870B9 (en) 2022-09-28
NZ607282A (en) 2014-06-27
EP3556870A1 (en) 2019-10-23
US20120028264A1 (en) 2012-02-02
EP4083233A3 (en) 2023-01-25

Similar Documents

Publication Publication Date Title
JP7042784B2 (ja) 遺伝子発現を用いた前立腺癌の予後を定量化する方法
JP6351112B2 (ja) 前立腺癌の予後を定量化するための遺伝子発現プロフィールアルゴリズムおよび試験
US11551782B2 (en) Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer
US20250305058A1 (en) Algorithms and Methods for Assessing Late Clinical Endpoints in Prostate Cancer
AU2017268510A1 (en) Method for using gene expression to determine prognosis of prostate cancer
US20110287958A1 (en) Method for Using Gene Expression to Determine Colorectal Tumor Stage
HK40052881A (en) Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer
HK40011641B (en) Algorithms and methods for assessing late clinical endpoints in prostate cancer
HK1235085B (en) Method for using gene expression to determine prognosis of prostate cancer
NZ752676B2 (en) Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer